Breakthrough breast cancer treatment - PARP inhibitor, BRCA, and triple negative breast cancer

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 7, 2010, Pages 1187-1191

  Hashimoto, Kenji ^a   Tamura, Kenji ^a,b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b National Cancer Center Hospital   (United States)

Author keywords

Basal type; BRCA; PARP inhibitor; Triple negative breast cancer

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEMCITABINE; INIPARIB; PROGESTERONE RECEPTOR;

BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COMPARATIVE STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; HUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROGESTERONE NEGATIVE BREAST CANCER; PROGESTERONE RECEPTOR NEGATIVE BREAST CANCER; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRIPLE NEGATIVE BREAST CANCER;

EID: 79961117394     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
2. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001. (Pubitemid 32878711)
3. Sørlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423, 2003.
4. Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374, 2004.
5. Kreike B, van Kouwenhove M, Horlings H, et al: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9: R65, 2007.
6. Scully R and Livingston DM: In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408: 429-432, 2000.
7. Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921, 2005. (Pubitemid 40559006)
8. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, et al: Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 8: R38, 2006.
9. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20: 2310-2318, 2002.
10. Honeth G, Bendahl PO, Ringner M, et al: The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10: R53, 2008.
11. Ratnam K and Low JA: Current development of clinical inhibitors of poly (ADP-ribose) polymerase in oncology. Clin Cancer Res 13: 1383-1388, 2007. (Pubitemid 46450426)
12. Calabrese CR, Batey MA, Thomas HD, et al: Identification of potent nontoxic poly (ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res 9: 2711-2718, 2003. (Pubitemid 36842117)
13. Plummer R, Jones C, Middleton M, et al: Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 14: 7917-7923, 2008.
14. Fong PC, Boss DS, Yap TA, et al: Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134, 2009.